Mobile

Pembrolizumab or placebo in combination with chemoradiation (CRT) in subjects with locally advanced HNSCC

Mise à jour : Il y a 4 ans
Référence : EUCTR2016-003934-25

Femme et Homme

  • | Pays :
    • -
  • | Organes :
    • -
  • | Spécialités :
    • -

Extrait

To compare Event-free survival (EFS) per RECIST (Response Evaluation Criteria in Solid Tumors) 1.1 by blinded independent central review (BICR) in subjects treated with pembrolizumab in combination with CRT and subjects treated with placebo in combination with CRT.

Critère d'inclusion

  • Locally advanced head and neck squamous cell carcinoma (LA HNSCC)

Liens